|
|
A leading member of the U.S. Senate says that a diabetes expert who was asked to review a controversial study on the risk of Avandia side effects leaked its findings to the drug’s manufacturer, GlaxoSmithKline.
Read more...
Two U.S. pharmacy benefits managers have announced that they have dropped Avandia from the list of drugs they carry due to concerns about the side effects of the drug. Studies have linked Avandia to an increased risk of heart attack, congestive heart failure, osteoporosis and other conditions.
Read more...
A new study has found that reports of Avandia side effects to the Food and Drug Administration tripled in the month after the publication of an article detailing the heart risks of the drug. Experts say that the increase in reported cases of Avandia side effects is probably due to a greater awareness among doctors that the drug can lead to heart problems. The reports included cases of side effects among patients taking both Avandia and Avandamet, which contains the same active ingredient, rosiglitazone.
Read more...
The diabetes drug Avandia was the key topic of conversation at a recent meeting in Chicago of experts on the disease. The session at the annual meeting of the American Diabetes Association was scheduled in order to discuss a recent study in the New England Journal of Medicine, which found that Avandia could increase a patient’s risk of death by 64% and of heart attack by 43%.
Read more...
A leading Indian health official has announced that the country is considering a ban on the diabetes drug Avandia. Dr. M. Venkateswarulu, the Drug Controller General of India, says that if preliminary results from the agency’s monitoring of the side effects of Avandia shows a danger to Indian patients, doctors may be banned from prescribing it.
Read more...
|
|
